HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
trastuzumab
Sensitive: A2 - Guideline
Future Oncol - 6 days
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
HP + eribulin mesylate
Sensitive: C2 – Inclusion Criteria
Breast Cancer Res Treat - 1 week
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
albumin-bound paclitaxel
Sensitive: C2 – Inclusion Criteria
Clin Breast Cancer - 2 weeks
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
fam-trastuzumab deruxtecan-nxki
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
pembrolizumab + trastuzumab
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
pertuzumab/trastuzumab/hyaluronidase-zzxf
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Trazimera (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Herzuma (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Zercepac (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Zercepac (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
Zercepac (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
TCHP
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
TCH
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
trastuzumab
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
|
trastuzumab
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
Endometrial Cancer
Endometrial Cancer
|
trastuzumab
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
pertuzumab
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
HER2 inhibitor
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
AC-TH
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
lapatinib
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
HER2 inhibitor
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
AC-THP
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
TH
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab + pertuzumab
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
pyrotinib
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
trastuzumab + pyrotinib
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar)
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
trastuzumab + pertuzumab
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine + pertuzumab
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
Urothelial Cancer
Urothelial Cancer
|
RC48
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar)
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
nivolumab
Resistant: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
SYD985
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar)
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
TX05 (trastuzumab biosimilar)
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar)
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
EG12014 (trastuzumab biosimilar)
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar)
Sensitive: B - Late Trials
|
HER-2 positive
HER-2 positive
|
Small Cell Lung Cancer
Small Cell Lung Cancer
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
Endometrial Adenocarcinoma
Endometrial Adenocarcinoma
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
Non Small Cell Lung Cancer
NSCLC
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
pembrolizumab + trastuzumab
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
Colon Cancer
Colon Cancer
|
ado-trastuzumab emtansine
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
Esophageal Adenocarcinoma
Esophageal Adenocarcinoma
|
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
|
neratinib
Resistant: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
ado-trastuzumab emtansine
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
|
trastuzumab
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
Biliary Tract Cancer
Biliary Tract Cancer
|
Herzuma (trastuzumab biosimilar)
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
|
pyrotinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
pyrotinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
margetuximab + MGD013
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
PRS-343
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
PRS-343
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
PRS-343
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
bevacizumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
epirubicin
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
paclitaxel
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
HM 78136B
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
Gastric Adenocarcinoma
Gastric Adenocarcinoma
|
pembrolizumab + margetuximab
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
|
KN046 + KN026
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
neratinib + ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
|
pyrotinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
pyrotinib + SHR6390
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
pembrolizumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
afatinib
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
A166
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
|
A166
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
KN026
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
pembrolizumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
RC48
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
ARX788
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
trastuzumab + copanlisib
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
ASLAN001
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
BAT8001
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
|
palbociclib + ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
|
RC48
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
|
pyrotinib + SHR6390
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
Gastric Cancer
Gastric Cancer
|
trastuzumab + ramucirumab
Sensitive: C2 – Inclusion Criteria
|
